Navigation Links
VentiRx Pharmaceuticals Publishes Preclinical Data of Novel TLR8 Agonist, VTX-2337, Supporting Its Potential as an Immunotherapeutic Approach in Cancer
Date:1/23/2012

SEATTLE, Jan. 23, 2012 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of novel Toll-like receptor 8 (TLR8) agonists for the treatment of cancer, today announced the publication of preclinical data demonstrating that VTX-2337, the Company's lead small molecule, is a novel, highly potent and selective TLR8 agonist. VTX-2337 directly activates human myeloid dendritic cells (mDCs), monocytes and natural killer (NK) cells resulting in the production of high levels of mediators known to orchestrate adaptive anti-tumor responses. Data were published in the journal Clinical Cancer Research.

(Logo: http://photos.prnewswire.com/prnh/20120123/SF39404LOGO)

The findings clearly distinguish TLR8 from other human TLRs. TLR8 is expressed on human monocytes, macrophages and mDCs circulating in blood and lymph nodes as well as on dendritic cells that are prevalent throughout the tumor microenvironment. Results demonstrate that the direct activation of mDCs by VTX-2337 results in a uniquely robust production of inflammatory cytokines and chemokines that increase cell mediated immunity and potentially enhance the anticancer effect of standard chemotherapy. Additionally, VTX-2337 has a direct effect on NK cells and augments antibody dependent cellular toxicity (ADCC), which supports the opportunity of combining VTX-2337 with monoclonal antibodies where ADCC contributes to clinical efficacy.

"These preclinical findings underscore the potential of a TLR8 agonist as a promising novel agent for cancer immunotherapy," said Mary L. Disis, M.D., professor of medicine in oncology at the University of Washington and associate dean of translational science at the UW School of Medicine, and co-author of the publication. "This research provides validation for current clinical trials evaluating VTX-2337 in combination with existing cancer treat
'/>"/>

SOURCE VentiRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
2. VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
3. FierceBiotech Names VentiRx Pharmaceuticals as One of the Fierce 15 Biotech Companies of 2010
4. VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... TAMPA, Fla. , March 31, 2015  Oxis ... biotech cancer therapy development and commercialization, announced today Oxis ... of the trading of Oxis common shares on the ... the OTCQB under the symbol OXIS.   ... "As Oxis continues to move forward with its strategies ...
(Date:3/31/2015)... MIAMI , March 31, 2015 ... TALOS™, today announced a strategic partnership with ... solutions for clinical research in life sciences. Offering ... global CRO has deployed Medidata,s electronic data capture ... support Biorasi,s Phase I through IV global clinical ...
(Date:3/31/2015)... , March 31, 2015  Ajinomoto Althea, Inc. ... development and manufacturing services, announced today that ... companies to its growing list of partners ... products using Althea,s Crystalomics ® ... total of 4 out of 10 of ...
Breaking Medicine Technology:Oxis International Inc. Announces Request for Euronext Trading Suspension 2Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 2Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 3Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 4Althea's New Drug Formulation Technology Gains Attention from Two More Top Pharmaceutical Companies 2
... , ENGLEWOOD, Colo., Dec. 7 ... DoseEdge(TM), during this week,s ASHP Midyear Clinical Meeting (MCM). ... safety and pharmacy efficiency through the management of IV ... into current pharmacy practice and techniques, while providing a ...
... , CARLSBAD, Calif., Dec. 7 Genoptix, Inc. (Nasdaq: ... the Company,s participation at the Deutsche Bank 2009 MedTools Investor ... Mass. on December 9-10, 2009. , Genoptix,s EVP ... the Company on Wednesday, December 9, 2009. He will ...
Cached Medicine Technology:Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3Genoptix Announces Participation at Deutsche Bank 2009 MedTools Investor Conference 2
(Date:3/31/2015)... On March 26, 2015, Vogue Magazine UK, in an ... a look into the trend of young women undergoing ... . The article suggests that celebrity endorsements (Beyoncé is cited ... Kardashian and Kylie Jenner are the drivers behind this trend. ... influences on the self-esteem of teenagers. (see: goo.gl/NmaB4q) , “I ...
(Date:3/31/2015)... 2015 Dr. Andrew Lian-Jie ... American Board of Dermatology and fellowship trained Mohs ... at the National Cancer Institute of the National ... in internal medicine at the Emory University and ... Philadelphia. Dr. Li pursued further training in Mohs ...
(Date:3/31/2015)... At Summit Breast Care, their passion is to provide ... caring manner. , Summit Breast Care has achieved national recognition ... cancer. They treat thousands of patients annually, not just ... Their doctors continue to be recognized as ‘Top Doctors’ ... Breast Care were planted in the mind and spirit of ...
(Date:3/31/2015)... 31, 2015 Researchers at UC ... and humans: how human livers heal. The difference ... liver regeneration. Normally, mouse PPARa is far more ... mice to quickly regenerate damaged livers. However, the ... (FGF21) can boost the regenerative effects of human ...
(Date:3/31/2015)... Former 49ers linebacker Chris Borland turned more heads with his ... promising NFL career. In a March episode of SCI ... explores the curious case of Borland and the potential ... process that Borland and other football players will likely use ... and what impact, if any, he thinks this case will ...
Breaking Medicine News(10 mins):Health News:Cosmetic Surgery: Does Social Media Pressure Young Girls to Get Botox and Fillers? 2Health News:Dr. Andrew Li of Warren Skin Care Center Is Celebrating 3 Years Recognized as an "NJ Top Doc" 2Health News:Summit Breast Care is Celebrating Four Years as "NJ Top Docs" 2Health News:UC Davis Study Finds Protein May Improve Liver Regeneration 2Health News:UC Davis Study Finds Protein May Improve Liver Regeneration 3Health News:UC Davis Study Finds Protein May Improve Liver Regeneration 4Health News:Will Leitch and the Curious Case of Chris Borland on SCI TV 2Health News:Will Leitch and the Curious Case of Chris Borland on SCI TV 3
... The anti-AIDS drug market is currently dominated by ... country's largest pharmaceutical company, is planning to enter ... director for India and west Asia, S D ... launch Lamivudine, Nevirapine, Aabacavir and Indinavir products in ...
... Complication as its other name. Among the many complications that ... ulcer, as damage can be severe enough to require amputation. ... in disguise would be a new device that delivers a ... stimulation would help in the healing of foot ulcers. ...
... procedure widely used on knees can also repair damaged ... best known for repairing knee injuries, but it is ... it is a minimally invasive surgical technique it is ... relieve different ankle problems, including ligament damage, bone chips ...
... techniques are being developed on a daily basis. One of ... those suffering from a degenerative eye condition. This degenerative condition ... fluid, causing scarring and loss of vision. ,Eye specialists ... Therapy, which has a lower risk rate of damaging the ...
... Paracetamol, whose active ingredient is Acetaminophen is found effective ... lowers body temperature in people who have had a ... Netherlands. ,Rise in the body temperature during the ... manifest as fever, has been linked to poorer outcomes ...
... pot of gold by making cheap anti-AIDS drugs. This ... escalate in coming days. ,The large number of ... drugs and market it in India and abroad by ... market, currently dominated by Mumbai-based Cipla, witnessed the entry ...
Cached Medicine News:Health News:Arthroscopy for Ankles 2
Fortitude as a unique complement to the spinal concepts family of products....
Caspar cervical retractor (lamina spreader), counter-retractor complete with 5 blades and forceps. Height: max. 165 mm, Maximal spread: 85 mm...
Cervical retractor with double finger hold, 3 depth 75 mm. Smooth...
Scoville cervical disc retractor, self-retaining with ratchet action....
Medicine Products: